[111In]In-PDI2

N/A

Report date: 2025/10/20 14:18:47

NME

Base Information

Drug Name[111In]In-PDI2

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNihon Medi-Physics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNihon Medi-Physics Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A